for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Seelos Therapeutics Inc

SEEL.OQ

Latest Trade

0.98USD

Change

-0.04(-3.51%)

Volume

92,619

Today's Range

0.95

 - 

1.02

52 Week Range

0.42

 - 

2.25

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
1.02
Open
1.01
Volume
92,619
3M AVG Volume
33.02
Today's High
1.02
Today's Low
0.95
52 Week High
2.25
52 Week Low
0.42
Shares Out (MIL)
44.95
Market Cap (MIL)
47.20
Forward P/E
-2.19
Dividend (Yield %)
--

Latest Developments

More

Seelos Announces Final Data From Phase I Pk/Pd Study Of Intranasal Racemic Ketamine

Seelos Therapeutics Announces Pricing Of $4.5 Mln Public Offering Of Common Stock

Seelos Therapeutics Announces Proposed Public Offering Of Common Stock

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Seelos Therapeutics Inc

Seelos Therapeutics, Inc., formerly Apricus Biosciences, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing technologies and therapeutics for the treatment of central nervous system, respiratory disorders. The Company is engaged in developing its lead programs SLS-002 and SLS-006. The Company is also engaged in developing several preclinical programs, which include SLS-008, SLS-007 SLS-010 and SLS-012. SLS-002 is intranasal racemic ketamine with two investigational new drug applications (INDs), for the treatment of suicidality in post-traumatic stress disorder (PTSD), and in depressive disorder. SLS-006 is engaged in advancing their product candidate into late stage trials as a monotherapy in early stage Parkinson's disease patients, and as an adjunctive therapy with reduced doses of Levodapa (L-DOPA). SLS-007 is a peptide-based approach, targeting the nonamyloid component core (NACore).

Industry

Biotechnology & Drugs

Contact Info

300 Park Avenue

NEW YORK, NY

10017

United States

+1.646.9986475

https://seelostherapeutics.com/

Executive Leadership

Raj Mehra

Chairman of the Board, President, Chief Executive Officer, Interim Chief Financial Officer

Warren Wasiewski

Chief Scientific Officer

Judith Dunn

Director

Brian W. Lian

Director

Daniel J. O'Connor

Director

Key Stats

2.00 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2019

0.0K

2020(E)

0.0K
EPS (USD)

2017

-29.700

2019

-2.520

2020(E)

-0.480
Price To Earnings (TTM)
--
Price To Sales (TTM)
125.86
Price To Book (MRQ)
6.83
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-284.58
Return on Equity (TTM)
-155.20

Latest News

Latest News

BRIEF-Seelos Therapeutics Announces Initiation Of Preclinical Study Of SLS-007 In Parkinson's Disease

* SEELOS THERAPEUTICS ANNOUNCES INITIATION OF PRECLINICAL STUDY OF SLS-007 IN PARKINSON'S DISEASE

BRIEF-Seelos Announces Final Data From Phase I Pk/Pd Study Of Intranasal Racemic Ketamine

* SEELOS THERAPEUTICS ANNOUNCES FINAL DATA FROM PHASE I PK/PD STUDY OF INTRANASAL RACEMIC KETAMINE (SLS-002) AND CLINICAL DEVELOPMENT PLANS

BRIEF-Seelos Therapeutics Announces Initiation Of Preclinical Study Of SLS-004 In Parkinson's Disease

* SEELOS THERAPEUTICS ANNOUNCES INITIATION OF PRECLINICAL STUDY OF SLS-004 IN PARKINSON’S DISEASE Source text for Eikon: Further company coverage:

BRIEF-Seelos Therapeutics Receives Rare Pediatric Disease Designation For SLS-005 In Sanfilippo Syndrome

* SEELOS THERAPEUTICS RECEIVES RARE PEDIATRIC DISEASE DESIGNATION FOR SLS-005 (TREHALOSE) IN SANFILIPPO SYNDROME Source text for Eikon: Further company coverage:

BRIEF-Seelos Therapeutics Receives Notice Of Allowance For U.S. Patent For Trehalose

* SEELOS THERAPEUTICS RECEIVES NOTICE OF ALLOWANCE FOR AN ADDITIONAL US PATENT FOR TREHALOSE (SLS-005) Source text for Eikon: Further company coverage:

BRIEF-Seelos Therapeutics Receives Notice Of Delisting Or Failure To Satisfy Continued Listing Rule From Nasdaq

* SEELOS THERAPEUTICS INC - ON APR 14, GOT NOTICE OF DELISTING OR FAILURE TO SATISFY A CONTINUED LISTING RULE OR STANDARD FROM NASDAQ Source text: (https://bit.ly/3cphNu7) Further company coverage:

BRIEF-Seelos Therapeutics Announces Pricing Of $4.5 Mln Public Offering Of Common Stock

* SEELOS THERAPEUTICS ANNOUNCES PRICING OF $4.5 MILLION PUBLIC OFFERING OF COMMON STOCK

BRIEF-Seelos Therapeutics Announces Proposed Public Offering Of Common Stock

* SEELOS THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK Source text for Eikon: Further company coverage:

BRIEF-Seelos Therapeutics Announces European Medicines Agency Guidance To Design An Open-Label Study For Sls-005

* SEELOS THERAPEUTICS ANNOUNCES EUROPEAN MEDICINES AGENCY GUIDANCE TO DESIGN AN OPEN-LABEL PIVOTAL STUDY FOR SLS-005 IN SANFILIPPO SYNDROME

BRIEF-Seelos Therapeutics Receives Notice Of Allowance For Composition Of Matter Patent For SLS-007

* SEELOS THERAPEUTICS RECEIVES NOTICE OF ALLOWANCE FOR COMPOSITION OF MATTER PATENT FOR SLS-007 Source text for Eikon: Further company coverage:

BRIEF-Seelos Therapeutics Announces Additional Interim Data From Phase I Studies Of Intranasal Racemic Ketamine

* SEELOS THERAPEUTICS ANNOUNCES ADDITIONAL INTERIM DATA FROM PHASE I STUDIES OF INTRANASAL RACEMIC KETAMINE (SLS-002)

BRIEF-Seelos Therapeutics Announces Pricing Of $5 Mln Public Offering Of Common Stock

* SEELOS THERAPEUTICS ANNOUNCES PRICING OF $5 MILLION PUBLIC OFFERING OF COMMON STOCK

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up